2023 Year In Review

As we approach the close of another year, it’s time to reflect on our exceptional journey at IMA Clinical Research and celebrate the achievements that have defined 2023 as a year of remarkable growth, dedication, and inclusivity.

Our commitment to advancing medical science, expanding patients’ access to advanced medicines, and improving healthcare powered a journey of expansion. Early this year, we gained nine new research clinics with our acquisitions of Accelemed Research Institute in Austin, TX and Clinical Trials of America sites throughout Louisiana and North Carolina. These facilities broaden research opportunities and accelerate startup processes. Furthermore, we expanded our Warren, NJ and San Antonio, TX sites into state-of-the-art facilities. This overall expansion reflects our dedication to promoting growth and ensuring the highest quality research for years to come.

These acquisitions were followed by the appointment of our new Executive Vice President, Dana Poff, who has enhanced our operational efficiencies since joining us and will continue to accelerate our substantial growth and expansion. Additionally, we hired fifteen seasoned Clinical Research Investigators to expand our therapeutic reach and add depth to our investigator bench. Their contributions, along with the existing leadership and staff, will further propel company growth and enable the delivery of high-quality outcomes.

IMA Clinical Research believes that diversity is not only a necessity to ensure balanced data to support approvals for new medical treatments but also a cornerstone of innovation. In 2023, we took meaningful steps to promote diversity and inclusion within our organization through inclusive hiring practices and by engaging with patients from diverse cultural backgrounds in the community. We celebrate the richness of perspectives, backgrounds, and experiences that our team members bring to the table. Embracing diversity has not only enriched our work environment but has also enhanced the quality and breadth of our research endeavors by helping us reflect the diversity in the communities we support.

‍In 2023, the Society for Clinical Research Sites (SCRS) welcomed IMA Clinical Research as a Global Impact Partner. The partnership offers IMA Clinical Research the opportunity to make an even greater impact on the global clinical research landscape through exclusive access to opportunities like the Digital Innovation Initiative and the Diversity Awareness Program.

As we turn the page to a new year, the spirit of progress, dedication, and inclusivity will continue to drive IMA Clinical Research forward. We anticipate exciting new research opportunities, expanded training initiatives, further physical expansion, and a continued commitment to diversity and inclusion. Our unwavering dedication to advancing medical knowledge remains as strong as ever. Our aim is clear: to solidify IMA as the preeminent research network in the nation. I look forward to stepping into the New Year with you and making 2024 our best year yet – Cheers!